Amarantus Bioscience Holdings Inc (AMBS)

[breezy1]

IP for Treatment must be worth 1billion on Paper at least.

Dr. Arendt has filed international patent applications on the concepts of modulating the expression of P16 in the brains of patients of Alzheimer's disease using gene therapy. P16 is a cell cycle protein that assists in maintaining and nurturing synaptic connections that is hypothesized to be at the root of Alzheimer's pathology. The Company is currently developing an Alzheimer's blood diagnostic LymPro Test® capable of identifying cell cycle dysregulation by harvesting peripheral blood lymphocytes. This option agreement opens the possibility of a targeted therapeutic on those Alzheimer's patients that have tested positive for LymPro. - See more at: http://globenewswire.com/news-release/2014/08/01/655409/10092519/en/Amarantus-Acquires-Exclusive-Option-to-License-Alzheimer-s-Therapeutic-IP-of-Dr-Thomas-Arendt-From-University-of-Leipzig.html#sthash.SKn0GtWn.dpuf